NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients

Fore Biotherapeutics

Status: Completed

Conditions: Lung Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02274025

TISS001

Details and patient eligibility

About

NovellusDx technology identifies tumor-specific driver mutations, but unlike sequencing-based tests, NovellusDx has a functional assay that detects dis-regulated translocation of mutated signaling proteins to the nucleus. This allows NovellusDx to identify functionally-impactful driver mutations regardless of whether the mutation has previously been described or linked to a tumor type.

Enrollment: 20 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients that are suspected to have lung cancer and are eligible for biopsy, surgical intervention or pleural fluid suction

Exclusion criteria

• Patients without lung cancer